Literature DB >> 16362268

Extended and standard supraglottic laryngectomies: a review of 110 patients.

Jean-Michel Prades1, Pierre-Gilles Simon, Andrei P Timoshenko, Jean-Marc Dumollard, Thierry Schmitt, Christian Martin.   

Abstract

The purpose of this study was to compare functional and oncological results of extended and standard supraglottic laryngectomies. One hundred ten patients with supraglottic carcinoma were treated. A standard supraglottic laryngectomy (SSL), a laterally extended supraglottic laryngectomy (LESL) and an anteriorly extended supraglottic laryngectomy (AESL) were performed on 32, 47 and 31 patients, respectively. Indications for postoperative radiotherapy included positive surgical margins (23% of patients) and/or node metastasis (63% of patients). Local recurrence occurred in 13% of SSL, 15% of LESL and 17% of AESL patients. Pulmonary complications due to aspiration were observed in 6% of SSL, 15% of LESL and 19% of AESL. The overall 5-year cure rates were 63% for SSL, 45% for LESL and 47% for the AESL procedures. Extended supraglottic laryngectomies provided as good a local tumor control as SSL. Extension to the hypopharynx (LESL) and to the vallecula (AESL) showed more frequent pulmonary complications and reduced cure rates.

Entities:  

Mesh:

Year:  2005        PMID: 16362268     DOI: 10.1007/s00405-004-0882-1

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  34 in total

1.  Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an alternative to surgery.

Authors:  W M Mendenhall; J T Parsons; A A Mancuso; S P Stringer; N J Cassisi
Journal:  Head Neck       Date:  1996 Jan-Feb       Impact factor: 3.147

2.  Partial laryngectomy and radiotherapy for supraglottic cancer: a conservative approach.

Authors:  C A Spaulding; W C Constable; P A Levine; R W Cantrell
Journal:  Ann Otol Rhinol Laryngol       Date:  1989-02       Impact factor: 1.547

3.  Interest in frozen section examination of margins and lymph nodes in laryngeal surgery.

Authors:  M Remacle; M Hamoir; E Marbaix; N Deggouj; Y Frederickx
Journal:  J Laryngol Otol       Date:  1988-09       Impact factor: 1.469

4.  Exclusive surgery versus postoperative radiotherapy for supraglottic cancer.

Authors:  Erik Esposito; Sergio Motta; Gaeto Motta
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2002 May-Jun       Impact factor: 1.538

5.  Carcinoma of the supraglottic larynx: treatment results with radiotherapy alone or with planned neck dissection.

Authors:  Russell W Hinerman; William M Mendenhall; Robert J Amdur; Scott P Stringer; Douglas B Villaret; K Thomas Robbins
Journal:  Head Neck       Date:  2002-05       Impact factor: 3.147

6.  End results of a prospective trial on elective lateral neck dissection vs type III modified radical neck dissection in the management of supraglottic and transglottic carcinomas.

Authors: 
Journal:  Head Neck       Date:  1999-12       Impact factor: 3.147

7.  Quantitative analysis from CT is prognostic for local control of supraglottic carcinoma.

Authors:  J R Kraas; T E Underhill; R B D'Agostino; D W Williams; J A Cox; K M Greven
Journal:  Head Neck       Date:  2001-12       Impact factor: 3.147

8.  Endoscopic CO2 laser treatment of supraglottic carcinoma.

Authors:  R Puxeddu; S Pirri; P C Bacchi; G Salis; G P Ledda
Journal:  Acta Otorhinolaryngol Ital       Date:  2003-12       Impact factor: 2.124

9.  The impact of bilateral neck dissection on pattern of recurrence and survival in supraglottic carcinoma.

Authors:  P C Weber; J T Johnson; E N Myers
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1994-07

10.  Supraglottic laryngectomy with or without postoperative radiotherapy in supraglottic carcinomas.

Authors:  C Suárez; J P Rodrigo; J Herranz; J L Llorente; J A Martínez
Journal:  Ann Otol Rhinol Laryngol       Date:  1995-05       Impact factor: 1.547

View more
  9 in total

1.  Supraglottic laryngectomy: analysis of 267 cases.

Authors:  Maria Agustina Sevilla; Juan Pablo Rodrigo; José Luis Llorente; Rubén Cabanillas; Fernando López; Carlos Suárez
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-08-08       Impact factor: 2.503

2.  Functional outcomes of supraglottic squamous cell carcinoma treated by transoral laser microsurgery compared with horizontal supraglottic laryngectomy in patients younger and older than 65 years.

Authors:  C M Chiesa Estomba; F A Betances Reinoso; A I Lorenzo Lorenzo; J L Fariña Conde; J Araujo Nores; C Santidrian Hidalgo
Journal:  Acta Otorhinolaryngol Ital       Date:  2016-12       Impact factor: 2.124

Review 3.  Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis.

Authors:  Elisabeth Rudolph; Gerhard Dyckhoff; Heiko Becher; Andreas Dietz; Heribert Ramroth
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-10-19       Impact factor: 2.503

4.  Rehabilitation of dysphagia following head and neck cancer.

Authors:  Barbara R Pauloski
Journal:  Phys Med Rehabil Clin N Am       Date:  2008-11       Impact factor: 1.784

5.  Functional organ preservation in laryngeal and hypopharyngeal cancer.

Authors:  Petra Ambrosch; Asita Fazel
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-04-26

Review 6.  Evidence and evidence gaps of laryngeal cancer surgery.

Authors:  Susanne Wiegand
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

Review 7.  Limitations and Opportunities in Open Laryngeal Organ Preservation Surgery: Current Role of OPHLs.

Authors:  Giovanni Succo; Erika Crosetti
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

Review 8.  Current Status of Organ Preservation in Carcinoma Larynx.

Authors:  Tapesh Bhattacharyya; Cessal Thommachan Kainickal
Journal:  World J Oncol       Date:  2018-05-01

9.  Transoral Laser Microsurgery for Supraglottic Cancer.

Authors:  Petra Ambrosch; Mireia Gonzalez-Donate; Asita Fazel; Claudia Schmalz; Jürgen Hedderich
Journal:  Front Oncol       Date:  2018-05-09       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.